Concepedia

Author

Sophia Hober

KTH Royal Institute of TechnologyORCID

Also Known As

S Hober, S. Hober, Sophia Hober, Sophia Hober,

268

Publications

34.3K

Citations

47

H-Index

140

Concepts

All Affiliations

KTH Royal Institute of TechnologyUppsala UniversityAlbaNovaScience for Life LaboratoryKarolinska Institutet
SH

About

Sophia Hober is an author at KTH Royal Institute of Technology specializing in medicine, immunology, and protein engineering.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

37

4.8K

2

Natural Sciences

14

20

570

3

Engineering

11

11

558

4

Health Sciences

3

3

3.5K

5

Public Health

1

1

26

Sophia Hober

×

123

Publications

29.1K

Citations

43

H-Index

YearCitations

Tissue-based map of the human proteome

Mathias Uhlén, Linn Fagerberg, Björn M. Hallström,

Science

2015

15.3K

A pathology atlas of the human cancer transcriptome

Mathias Uhlén, Cheng Zhang, Sunjae Lee,

Science

2017

3.4K

A subcellular map of the human proteome

Peter Thul, Lovisa Åkesson, Mikaela Wiking,

Science

2017

2.9K

A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics

Mathias Uhlén, Erik Björling, Charlotta Agaton,

Molecular & Cellular Proteomics

2005

1.5K

The human secretome

Mathias Uhlén, Max Karlsson, Andreas Hober,

Science Signaling

2019

478

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Sebastian Havervall, Axel Rosell, Mia Phillipson,

JAMA

2021

411

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden

Ann‐Sofie Rudberg, Sebastian Havervall, Anna Månberg,

Nature Communications

2020

324

Towards a human proteome atlas: High‐throughput generation of mono‐specific antibodies for tissue profiling

Peter Nilsson, Linda Paavilainen, Karin Larsson,

PROTEOMICS

2005

269

A global view of protein expression in human cells, tissues, and organs

Fredrik Pontén, Marcus Gry, Linn Fagerberg,

Molecular Systems Biology

2009

222

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman, Ola Blennow, Lotta Hansson,

EBioMedicine

2021

219

Page 1